Dynamic Changes in Microbiome Composition Following Mare’s Milk Intake for Prevention of Collateral Antibiotic Effect
Kushugulova A. Löber U. Akpanova S. Rysbekov K. Kozhakhmetov S. Khassenbekova Z. Essex M. Nurgozhina A. Nurgaziyev M. Babenko D. Markó L. Forslund S.K.
21 April 2021Frontiers Media S.A.
Frontiers in Cellular and Infection Microbiology
2021#11
Introduction: Probiotics and prebiotics are widely used for recovery of the human gut microbiome after antibiotic treatment. High antibiotic usage is especially common in children with developing microbiome. We hypothesized that dry Mare’s milk, which is rich in biologically active substances without containing live bacteria, could be used as a prebiotic in promoting microbial diversity following antibiotic treatment in children. The present pilot study aims to determine the impacts of dry Mare’s milk on the diversity of gut bacterial communities when administered during antibiotic treatment and throughout the subsequent recovery phase. Methods: Six children aged 4 to 5 years and diagnosed with bilateral bronchopneumonia were prescribed cephalosporin antibiotics. During the 60 days of the study, three children consumed dry Mare’s milk whereas the other three did not. Fecal samples were collected daily during antibiotic therapy and every 5 days after antibiotic therapy. Total DNA was isolated and taxonomic composition of gut microbiota was analyzed by 16S rRNA amplicon sequencing. To assess the immune status of the gut, stool samples were analyzed by bead-based multiplex assays. Results: Mare’s milk treatment seems to prevent the bloom of Mollicutes, while preventing the loss of Coriobacteriales. Immunological analysis of the stool reveals an effect of Mare’s milk on local immune parameters under the present conditions. © Copyright
16S rRNA gene sequencing , collateral antibiotic effect , intestinal immunity , mare’s milk , microbiome
Text of the article Перейти на текст статьи
Laboratory of Human Microbiome and Longevity, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan
Kazakhstan Society of Human Microbiome Researchers, Nur-Sultan, Kazakhstan
SaumalBioTech, Nur-Sultan, Kazakhstan
Experimental and Clinical Research Center, a Cooperation of Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
Department of Pediatric Diseases with Courses in Cardio-Rheumatology and Gastroenterology, Nur-sultan (Astana) Medical University, Nur-Sultan, Kazakhstan
Laboratory of Innate Immunity, Department of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin, Berlin, Germany
Research Center, Karaganda Medical University, Karagandy, Kazakhstan
Structural and Computational Biology Unit, The European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
Laboratory of Human Microbiome and Longevity
Kazakhstan Society of Human Microbiome Researchers
SaumalBioTech
Experimental and Clinical Research Center
Charité-Universitätsmedizin Berlin
Max Delbrück Center for Molecular Medicine in the Helmholtz Association
DZHK (German Centre for Cardiovascular Research)
Department of Pediatric Diseases with Courses in Cardio-Rheumatology and Gastroenterology
Laboratory of Innate Immunity
Research Center
Structural and Computational Biology Unit
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026